Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival
Research output: Contribution to journal › Journal article › Research › peer-review
The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.
| Original language | English |
|---|---|
| Journal | Journal of Thoracic Oncology |
| Volume | 7 |
| Issue number | 1 |
| Pages (from-to) | 249-56 |
| Number of pages | 8 |
| ISSN | 1556-0864 |
| DOIs | |
| Publication status | Published - 2012 |
ID: 40139448